Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
about
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@en
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@nl
type
label
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@en
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@nl
prefLabel
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@en
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@nl
P2093
P2860
P1433
P1476
Phase II Study of BEZ235 versu ...... creatic Neuroendocrine Tumors.
@en
P2093
Ana Custodio
Andrew E Hendifar
Annemiek Walenkamp
Catherine Lombard-Bohas
Enrique Grande
Heinz-Josef Klümpen
Herve Salomon
James C Yao
Jaume Capdevila
Nicholas Reed
P2860
P356
10.1634/THEONCOLOGIST.2017-0144
P577
2017-12-14T00:00:00Z